Clinical trial · Observational
A Prospective and Observational Cohort Study to Evaluate the Treatment Model and Medical Economics of Advanced Gastric Cancer Chemotherapy in Clinical Practice in China
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multi-center, prospective and observational clinical study. Eligible patients will accept generalized chemotherapy according to the investigator's assessment. Information related to the treatment, including medication, disease condition, expenses, etc. will be periodically collected. Follow-up at 2-month intervals will be periodically performed to continually collect information about the disease progression, subsequent treatment and survival until death or completion of the study. Recruited patients will fill out questionnaires about quality of life before initiation of treatment, at Cycle 3 and completion of first-line treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Clinical chemo-drugs | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- chemotherapy
- description
- Eligible patients will accept generalized chemotherapy according to the investigator's assessment.
- interventionNames
- Drug: Clinical chemo-drugs
Primary outcomes (1)
- measure
- chemotherapy regimen
- timeFrame
- 2 months
- description
- To evaluate the treatment model (singel or doublet or triplet chemotherapy)of patients with advanced gastric cancer in China
Secondary outcomes (3)
- measure
- overall survival
- timeFrame
- 2 months
- description
- OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 2 months till death or lost
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient has histologically confirmed locally-advanced or recurrent and/or metastatic gastric or esophagogastric junction adenocarcinoma, has missed the opportunity of surgical excision, making curative therapy impossible. 2. The informed consent form is signed. 3. A specimen of tumor tissue (puncture biopsy or surgical specimen) is available. 4. ECOG performance status is 0, 1 or 2. 5. The patient's general conditions and functions of important organs allow generalized chemotherapy according to the investigator's judgment 6. The patient is aged≥18 Exclusion Criteria: 1. The patient is known to be allergic to any study drug. 2. The patient is recruited in other clinical study or is planned to participate into other clinical study. 3. The patient has previously accepted chemotherapy against advanced or metastatic diseases (the patient may be recruited if the previous adjuvant therapy/neoadjuvant therapy was completed more than 6 months before inclusion).
References
Publications (0)
Data not yet available